Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ETNB Stock Summary
In the News

Ra Capital Management Now Owns 18% of 89bio
Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).

Tech Stocks Are Surging
The Nasdaq 100 is on a tear

A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015 to 27 million in 2030.

89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering
89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering appeared first on Pulse 2.0.

Why Shares of 89bio Soared This Week
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.

89bio's public stock offering upsized by 38%, priced at a 4% discount
89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92 million common shares at $16.25 each, to raise $275.0 million.

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.

Biotech Stock Surges on Mid-Stage Drug Trial Success
The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease -- met the main objectives of a mid-stage study.

Why Is 89bio (ETNB) Stock Up 34% Today?
89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.

89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared first on Investor's Business Daily.
ETNB Financial details
ETNB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -7.6 | -24.49 | -3.08 | -5.6 | -2.93 | |
Operating cash flow per share | -5.86 | -10.86 | -2.87 | -4.77 | -2.33 | |
Free cash flow per share | -5.88 | -10.92 | -2.88 | -4.78 | -2.33 | |
Cash per share | 5.28 | 39.82 | 12.72 | 9.37 | 5.41 | |
Book value per share | -7.55 | 38.37 | 12.62 | 7.83 | 4.36 | |
Tangible book value per share | -7.55 | 38.37 | 12.62 | 7.83 | 4.36 | |
Share holders equity per share | -7.55 | 38.37 | 12.62 | 7.83 | 4.36 | |
Interest debt per share | 0 | 0 | 0 | 1.21 | 0.07 | |
Market cap | 44.25M | 61.63M | 392.06M | 210.27M | 443.08M | |
Enterprise value | 33.01M | -31.71M | 293.88M | 177.23M | 388.18M | |
P/E ratio | -2.74 | -1.07 | -7.92 | -2.33 | -4.34 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.55 | -2.42 | -8.48 | -2.74 | -5.46 | |
PFCF ratio | -3.54 | -2.41 | -8.46 | -2.74 | -5.46 | |
P/B Ratio | -2.76 | 0.69 | 1.93 | 1.67 | 2.92 | |
PTB ratio | -2.76 | 0.69 | 1.93 | 1.67 | 2.92 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.05 | 0.55 | -5.94 | -1.97 | -3.84 | |
EV to operating cash flow | -2.65 | 1.25 | -6.35 | -2.31 | -4.79 | |
EV to free cash flow | -2.64 | 1.24 | -6.34 | -2.31 | -4.79 | |
Earnings yield | -0.37 | -0.93 | -0.13 | -0.43 | -0.23 | |
Free cash flow yield | -0.28 | -0.42 | -0.12 | -0.37 | -0.18 | |
Debt to equity | -1.71 | 0.06 | 0.04 | 0.29 | 0.3 | |
Debt to assets | 2.41 | 0.06 | 0.04 | 0.22 | 0.23 | |
Net debt to EBITDA | 0.7 | 1.63 | 1.98 | 0.37 | 0.54 | |
Current ratio | 2.6 | 17 | 25.91 | 8.29 | 7.97 | |
Interest coverage | 0 | 0 | 0 | 0 | -53.2 | |
Income quality | 0.77 | 0.44 | 0.93 | 0.85 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -6.5 | -8.18 | -2.1 | -0.8 | 0.01 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 35.94 | 145.42 | 29.55 | 31.41 | 16.96 | |
ROIC | 1.2 | 0.29 | -3.9 | -1.77 | -1.39 | |
Return on tangible assets | -1.42 | -0.6 | -0.23 | -0.55 | -0.52 | |
Graham Net | -7.61 | 37.42 | 12.22 | 7.1 | 4.11 | |
Working capital | 6.96M | 89.72M | 202.09M | 142.45M | 171.47M | |
Tangible asset value | -16.06M | 89.94M | 202.96M | 125.96M | 151.83M | |
Net current asset value | -16.11M | 89.72M | 202.09M | 125.52M | 151.09M | |
Invested capital | 0 | 0 | 0 | 0.15 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 1.25M | 1.53M | 4.45M | 9.67M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 1.01 | -0.64 | -0.24 | -0.72 | -0.67 | |
Capex per share | -0.02 | -0.06 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.3 | -1.26 | -1.23 | -0.57 | -2.16 | |
Operating cash flow per share | -1.39 | -1.2 | -0.73 | -0.31 | -1.9 | |
Free cash flow per share | -1.4 | -1.2 | -0.73 | -0.31 | -1.9 | |
Cash per share | 7.44 | 6.2 | 6.85 | 4.09 | 5.41 | |
Book value per share | 6.22 | 5.05 | 3.94 | 3.23 | 4.36 | |
Tangible book value per share | 6.22 | 5.05 | 3.94 | 3.23 | 4.36 | |
Share holders equity per share | 6.22 | 5.05 | 3.94 | 3.23 | 4.36 | |
Interest debt per share | 0.96 | 0.96 | 0.97 | 0.42 | 0.07 | |
Market cap | 264.82M | 76.68M | 65.53M | 273.6M | 443.08M | |
Enterprise value | 231.79M | 41.26M | 24.57M | 221.22M | 388.18M | |
P/E ratio | -2.52 | -0.75 | -0.65 | -2.55 | -1.47 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -9.38 | -3.15 | -4.42 | -18.47 | -6.69 | |
PFCF ratio | -9.37 | -3.15 | -4.42 | -18.47 | -6.68 | |
P/B Ratio | 2.1 | 0.75 | 0.82 | 1.79 | 2.92 | |
PTB ratio | 2.1 | 0.75 | 0.82 | 1.79 | 2.92 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -8.78 | -1.62 | -0.98 | -8.26 | -5.23 | |
EV to operating cash flow | -8.21 | -1.7 | -1.66 | -14.93 | -5.86 | |
EV to free cash flow | -8.2 | -1.69 | -1.66 | -14.93 | -5.86 | |
Earnings yield | -0.1 | -0.33 | -0.38 | -0.1 | -0.17 | |
Free cash flow yield | -0.11 | -0.32 | -0.23 | -0.05 | -0.15 | |
Debt to equity | 0.29 | 0.32 | 0.84 | 0.31 | 0.3 | |
Debt to assets | 0.22 | 0.24 | 0.46 | 0.24 | 0.23 | |
Net debt to EBITDA | 1.25 | 1.39 | 1.64 | 1.96 | 0.74 | |
Current ratio | 8.29 | 7.36 | 5.45 | 5.81 | 7.97 | |
Interest coverage | 0 | 0 | 0 | 0 | -39.13 | |
Income quality | 1.07 | 0.95 | 0.59 | 0.55 | 0.88 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.29 | -0.33 | 0.06 | 0 | 0.01 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 13.47 | 11.95 | 10.45 | 6.42 | 14.56 | |
ROIC | -0.51 | -1.16 | -1.15 | -0.65 | -1.02 | |
Return on tangible assets | -0.16 | -0.19 | -0.17 | -0.13 | -0.38 | |
Graham Net | 5.64 | 4.58 | 3.53 | 3.08 | 4.11 | |
Working capital | 142.45M | 117.01M | 119.67M | 165.43M | 171.47M | |
Tangible asset value | 125.96M | 102.74M | 80.19M | 152.58M | 151.83M | |
Net current asset value | 125.52M | 102.39M | 79.16M | 151.85M | 151.09M | |
Invested capital | 0.15 | 0.19 | 0.25 | 0.13 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 9.68M | 5.63M | 4.66M | 9.53M | 13.33M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.21 | -0.25 | -0.31 | -0.18 | -0.5 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ETNB Frequently Asked Questions
What is 89bio, Inc. stock symbol ?
89bio, Inc. is a US stock , located in San francisco of Ca and trading under the symbol ETNB
What is 89bio, Inc. stock quote today ?
89bio, Inc. stock price is $15.23 today.
Is 89bio, Inc. stock public?
Yes, 89bio, Inc. is a publicly traded company.